PIK3CD Antibody

說明書

中文名稱：

PIK3CD兔多克隆抗體
貨號：

CSB-PA193486
規格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using CSB-PA193486(PIK3CD Antibody) at dilution 1/35, on the right is treated with synthetic peptide. (Original magnification: ×200)
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

O00329
基因名：

PIK3CD
別名：

5-bisphosphate 3-kinase 110 kDa catalytic subunit delta antibody; 5-bisphosphate 3-kinase catalytic subunit delta isoform antibody; APDS antibody; GRB1 antibody; IMD14 antibody; p110d antibody; p110delta antibody; p110dp85a antibody; p85-ALPHA antibody; Phosphatidylinositol 3 kinase catalytic delta polypeptide antibody; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit delta isoform antibody; Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit delta antibody; Phosphatidylinositol 4,5 bisphosphate 3 kinase; catalytic subunit delta antibody; Phosphatidylinositol 45 bisphosphate 3 kinase catalytic subunit delta isoform antibody; Phosphatidylinositol-4 antibody; Phosphoinositide 3 kinase B antibody; Phosphoinositide 3 kinase C antibody; Phosphoinositide 3 kinase catalytic delta polypeptide antibody; Phosphoinositide 3 kinase; catalytic; delta polypeptide variant p37delta antibody; PI3 kinase p110 subunit delta antibody; PI3-kinase subunit delta antibody; PI3K antibody; PI3K-delta antibody; PI3Kdelta antibody; Pik3cd antibody; PIK3R1 antibody; PK3CD antibody; PK3CD_HUMAN antibody; PtdIns 3 kinase p110 antibody; PtdIns 3 kinase subunit p110 delta antibody; PtdIns-3-kinase subunit delta antibody; PtdIns-3-kinase subunit p110-delta antibody
宿主：

Rabbit
反應種屬：

Human,Mouse
免疫原：

Synthetic peptide of Human PIK3CD
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產品提供形式：

Liquid
應用范圍：

ELISA,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:1000-1:2000
IHC	1:25-1:100

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Mediates immune responses. Plays a role in B-cell development, proliferation, migration, and function. Required for B-cell receptor (BCR) signaling. Mediates B-cell proliferation response to anti-IgM, anti-CD40 and IL4 stimulation. Promotes cytokine production in response to TLR4 and TLR9. Required for antibody class switch mediated by TLR9. Involved in the antigen presentation function of B-cells. Involved in B-cell chemotaxis in response to CXCL13 and sphingosine 1-phosphate (S1P). Required for proliferation, signaling and cytokine production of naive, effector and memory T-cells. Required for T-cell receptor (TCR) signaling. Mediates TCR signaling events at the immune synapse. Activation by TCR leads to antigen-dependent memory T-cell migration and retention to antigenic tissues. Together with PIK3CG participates in T-cell development. Contributes to T-helper cell expansion and differentiation. Required for T-cell migration mediated by homing receptors SELL/CD62L, CCR7 and S1PR1 and antigen dependent recruitment of T-cells. Together with PIK3CG is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in NK cell receptor activation. Plays a role in NK cell maturation and cytokine production. Together with PIK3CG is involved in neutrophil chemotaxis and extravasation. Together with PIK3CG participates in neutrophil respiratory burst. Plays important roles in mast-cell development and mast cell mediated allergic response. Involved in stem cell factor (SCF)-mediated proliferation, adhesion and migration. Required for allergen-IgE-induced degranulation and cytokine release. The lipid kinase activity is required for its biological function. Isoform 2 may be involved in stabilizing total RAS levels, resulting in increased ERK phosphorylation and increased PI3K activity.
基因功能參考文獻：
1. findings suggest that the increased circulating transitional B cells characteristic of PIK3CD5 are related to abnormal B-cell maturation in the bone marrow PMID: 27697496
2. Data show that mRNA translation stress induces E2F transcription factor 1 (E2F1) via PI3-kinase p110 subunit delta (PI3Kdelta). PMID: 29235459
3. our work describing two new PIK3CD gain-of-function mutations, E81K and G124D, demonstrated that mutations in the ABD and its linker region lead to APDS1. PMID: 28428270
4. CXCR4 can induce PI3Kdelta inhibitor resistance in ABC DLBCL. PMID: 29472546
5. results suggest that the different isoforms of the PI3K p110 subunit could be therapeutic targets for primary and metastatic colon cancer and that regulation of the NRD1/ADAM signaling pathway controls lipogenesis-mediated EMT in IGF-1-stimulated colon cancer cells. PMID: 28819788
6. Results provide molecular insights into the conformational mechanisms by which PI3Kdelta is activated in primary immunodeficiencies and reveal how mutations in PIK3R1 (p85alpha) can specifically phenocopy gain-of-function mutations in PIK3CD (p110delta). PMID: 28167755
7. Idelalisib is a selective inhibitor of phosphatidylinositol-3-kinase delta (PI3Kdelta) that inhibits Hodgkin lymphoma growth and survival . Based on the above preclinical data, the current study evaluated the efficacy and safety of idelalisib in relapsed and refractory Hodgkin lymphoma . PMID: 28327905
8. PI3Kdelta and PI3Kgamma inhibition with IPI-145 has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK PMID: 27174919
9. Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. The data were confirmed in an in vivo experiment treating DLBCL xenografts with pimasertib and ibrutinib. PMID: 26961147
10. miR-26b inhibited the PI3K/AKT pathway by directly targeting PIK3CD, the gene encoding PI3Kdelta, in human T-ALL cell lines PMID: 28280276
11. Targeting PI3Kdelta or JAK may prove effective in reducing T-cell activation and the resulting cytokine production in asthma. PMID: 27716212
12. Our work defines SETD2 as a tumor suppressor gene in Hepatosplenic T-cell lymphoma (HSTL)and implicates genes including INO80 and PIK3CD in the disease PMID: 28122867
13. The findings, specifically frequent mutations of STAT5B, PIK3CD, and the histone methyltransferase SETD2, may help guide translational efforts to target hepatosplenic T-cell lymphoma PMID: 28373165
14. PI3K, independently of protein kinase B, has a role in parasite-induced netosis. One of the main isoforms involved is PI3Kdelta, which works in a reactive-oxygen-species-independent way. PMID: 27154356
15. The B-cell compartment in PI3K-delta syndrome patients is affected by the mutations in PIK3CD and PIK3R1. There is reduced differentiation beyond the transitional stage, increased AKT phosphorylation and increased apoptosis. PMID: 28104464
16. PI3Kdelta or Bruton's tyrosine kinase inhibitors increase genomic instability in normal and neoplastic B cells by an AID-dependent mechanism; this effect should be carefully considered, as such inhibitors can be administered to patients for years PMID: 28199309
17. biased CD4(+) T cell differentiation was independent of any crosstalk between CD4(+) T cells and dendritic cells and was mediated via direct exposure of CD4(+) T cells to palmitate, leading to increased activation of a PI3K p110delta-Akt-dependent pathway upon priming. PMID: 28190771
18. miR-125b suppressed anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD expression. PMID: 28122310
19. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kdelta or PKCbeta signaling pathways. PMID: 26540567
20. We describe a family of two adults and three children with a gain of function mutation in PIK3CD, all with recurrent sinopulmonary infections and varied infectious and non-infectious complications. Sequencing of PIK3CD confirmed a known heterozygous mutation c3061G>A, p.E1021K in all affected family members. The two adults have primary sclerosing cholangitis without C. parvum infection. PMID: 25352054
21. study concludes that activating mutations in PIK3CD may cause immunodeficiency in patients with a complex phenotype combining defective B and T cell responses, but are less likely to be discovered in patients where only the humoral arm of the immune response is affected and naive T cell numbers are normal PMID: 26437962
22. work identifies FAK as a target of p110delta PI3K that links RhoA with PTEN and establishes for the first time that PTEN is a substrate of FAK-mediated Tyr phosphorylation PMID: 26251180
23. Studies indicate that phosphatidylinositol-45-bisphosphate 3-kinase 110 kDa catalytic subunit (PIK3CD p110delta) have been described (N334K, C416R, E525K and E1021K with the majority of cases carrying E1021K) as a cause for primary immunodeficiency. PMID: 26286043
24. Impaired signaling and protein synthesis through the PI3K catalytic subunit p110delta is an underlying molecular defect and potential treatment target in select autism spectrum disorders. PMID: 26770665
25. Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs. PMID: 26265781
26. Gestational diabetes mellitus is accompanied by leukocyte PIK3CD overexpression associated with reduced plasma LDL-C and TC levels, as well as with hyperglycaemia and elevated leukocyte SIRT1 mRNA. PMID: 24549598
27. These results collectively indicate that inducible PI3Kdelta plays a crucial role in persistent activation of PI3K-Akt in fibroblast-like synoviocytes, and in the formation of a hypertrophic synovial lining. PMID: 24716596
28. Data indicate a series of quinolinylpurines as potent and selective PI3Kdelta kinase inhibitors with in vivo efficacy as measured by two rodent disease models of inflammation and autoimmune disease. PMID: 25469863
29. Expression of functional S1PR1 is reduced by B cell receptor signaling and increased by inhibition of PIK3CD but not SYK or BTK in chronic lymphocytic leukemia cells. PMID: 25632006
30. The p110delta PI3K-selective compound CAL-101 (Idelalisib) did not inhibit markers of PI3K activity in cancer or stromal cells. PMID: 24648465
31. Patients with activated phosphoinositide 3-kinase delta syndrome (mutation in PIK3CD) develop B-cell lymphomas. PMID: 24698326
32. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. PMID: 24610295
33. PIK3CD was inversely correlated with miR-663 in glioblastoma specimens and predicted poor prognosis of patients with glioblastoma PMID: 24523440
34. PI3K p110delta uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of juvenile myelomonocytic leukemia. PMID: 24553178
35. PIK3CD is a target gene of miR-125b in Ewing's sarcoma cells. RT-PCR and western blot assays identify over-expression of miR-125b that suppresses the expression of PIK3CD mRNA and protein. PMID: 24517182
36. PI3Kdelta contributes to multiple aspects of the pathogenic FLS behavior in RA. These observations, together with previous findings that PI3Kdelta regulates FLS growth and survival PMID: 24470496
37. Study reveals functional and mechanistic links between miRNA-30b and oncogene KRAS, PIK3CD and BCL2 in the pathogenesis of colorectal carcinoma. PMID: 24293274
38. Data indicate that patients with combined immunodeficiency disease who share gain-of-function mutations in PIK3CD (p110delta), resulting in hyperactivation of mTOR signaling and skewed the differentiation of CD8+ T cells. PMID: 24165795
39. this study found E1021K in 17 patients with activated PI3K-delta syndrome (APDS), from seven unrelated families with, but not among 3346 healthy subjects. PMID: 24136356
40. The expression of PIK3CD is inversely correlated with miR-30a levels in metastatic colorectal carcinoma tissues. PMID: 23486085
41. These results suggest that PI3Kdelta mediates dsRNA-induced upregulation of B7-H1 without affecting the activation of NF-kappaB. PMID: 23660190
42. Studies indicate that the research with phosphoinositide 3-kinase p110-delta (p110delta) in chronic lymphocytic leukemia (CLL) have led to a more fundamental understanding of CLL signaling defects. PMID: 22711705
43. PIK3CD shows evidence of association with schizophrenia, and is a previously undescribed therapeutic target for the treatment of psychiatric disorders. PMID: 22689948
44. p37delta appears to be a new tumor-specific isoform of p110delta with growth-promoting properties PMID: 22020336
45. PI3 kinase delta is a key regulator of synoviocyte function in rheumatoid arthritis. PMID: 22433439
46. PI3K p110delta is important for TGFB1 induced production of the contractile proteins calponin and alpha-SMA and the proinflammatory cytokine IL-6 PMID: 22015454
47. present a detailed biochemical and bioinformatic characterization of p110delta gene regulation, demonstrating that PIK3CD has distinct promoters, some of which can be dynamically activated by pro-inflammatory mediators PMID: 22375552
48. Findings suggest that excessive PI3Kdelta activity is characteristic in Hodgkin lymphoma (HL) and support clinical evaluation of GS-1101, alone and in combination, as targeted therapy for HL. PMID: 22210877
49. p110delta-dependent translocation of exogenous CSF-1 to the nucleus-associated CSF-1Rs, correlating with a prominent role of p110delta in activation of the Rab5 GTPase, a key regulator of endocytic trafficking PMID: 22084313
50. Isoform specific targeting of PI3Kdelta may be beneficial in the treatment of glioblastoma multiforme by specifically inhibiting tumour cell migration capacity. PMID: 22079609
顯示更多

收起更多
相關疾?。?/div>
Activated PI3K-delta syndrome (APDS)
亞細胞定位：

Cytoplasm.
蛋白家族：

PI3/PI4-kinase family
組織特異性：

In humans, the highest levels of expression are seen in peripheral blood mononuclear cells, spleen, and thymus, and low levels of expression in testes, uterus, colon, and small intestine but not in other tissues examined including prostate, heart, brain,
數據庫鏈接：

HGNC: 8977

OMIM: 602839

KEGG: hsa:5293

STRING: 9606.ENSP00000366563

UniGene: Hs.518451

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human